Search COVID-19 Rapid Resource Center or explore resources sorted by Category or Content Type.


Less Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019

Cytokine release syndrome (CRS) mediated by IL-6 is a critical driver of COVID-19 mortality.

The authors review and discuss key immunologic effects of direct IL-6 blockade, downstream non-selective JAK inhibition, and selective JAK2 suppression to treat COVID-19-related CRS.

We provide evidence that selective targeting of IL-6 or JAK2 is well informed by existing data.

Authors: Betts BC; Young JW. Crit Care Explor 2020.


Estimated Time: 12:04 min

Categories: Epidemiology-Outcomes, Disaster,
Content Type: Articles,